
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc. has demonstrated robust quarter-over-quarter growth in its Cabometyx franchise, achieving a reported revenue of $515.2 million for the fourth quarter of fiscal year 2024, representing a 20% year-over-year increase. The company's strategic positioning in the oncology market, particularly its anticipated use in 30% of the second-line neuroendocrine tumor patient population, supports a strong potential for revenue expansion, with analysts estimating U.S. peak sales of approximately $290 million. Furthermore, the combination of Cabometyx with Opdivo has established it as the most prescribed tyrosine kinase inhibitor in renal cell carcinoma, enhancing Exelixis's growth outlook amidst favorable market conditions.
Bears say
Exelixis Inc faces significant challenges that negatively impact its stock outlook, primarily stemming from expectations regarding the market share of cabozantinib (Cabo) in key indications, which are projected to be much lower than previously anticipated in the first-line renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) settings. The firm is exposed to multiple risks, including potential R&D and regulatory setbacks, competition from new therapies, and diminishing sales for its current products, particularly cabozantinib, which may further diminish its revenue streams in the face of generic erosion. Additionally, concerns regarding the efficacy and tolerability of its pipeline candidate, zanzalintinib, along with the potential for long-term dilution risk, contribute to an uncertain financial outlook for Exelixis.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares